- Who we are
- About AHRI
- Vision and Mission
- Staff Directory
- News & Updates
- Work with us
- Contact Us
PhArmacoVIgilance Africa (PAVIA) is a consortium which has recently been funded by the European Developing countries Clinical Trials Partnership (EDCTP). The PAVIA project aims to strengthen pharmacovigilance (PV) in four African countries: Ethiopia, Nigeria, Swaziland and Tanzania. To achieve this aim, collaborative support will be harnessed across several institutions in Europe and Africa. In each of the participating countries, a uniquely designed active triangle will lead the project. This triangle will consist of an intense collaboration of;
i) National Medicine Regulatory Authority (including the national pharmacovigilance unit),
ii) National Public Health Programme introducing a new product and;
iii) Local Medical Research Institutes (MRI).
PAVIA will have its initial activities premisedon the introduction of new drugs and treatment regimens for multidrug-resistant tuberculosis (MDR-TB) by the National Tuberculosis Programs (NTPs). PAVIA’s focuswill include strengthening the processes of routine adverse event reporting in accordance with country policies that already exist (or which will be put in place or strengthened during the course of the PAVIA project). In addition, expert guidance will be provided on causality assessment, signal detection and training at the national and lower levels to support the linkage process between disease control programmes (notably the NTPs) and the National Regulatory Authorities/Pharmacovigilance Agencies.
At the end of the project,PAVIA will deliver a blueprint for strengthening pharmacovigilance that can serve other Sub-Sahara African countries.
The EDCTP beneficiaries under the PAVIA project are the Amsterdam Institute of Global Health, the Netherlands Pharmacovigilance Centre Lareb and the KNCV Tuberculosis Foundation (The Netherlands), the University of Verona (Italy), Tanzania Food and Drug Authority and Kilimanjaro Clinical Research Institute (Tanzania), University of Benin, Institute of Human Virology and National Agency for Food and Drug Administration Control (Nigeria), Baylor International Pediatric AIDS Initiative and Ministry of Health (Swaziland), Armauer Hansen Research Institute and Food, Medicine and Health Care Administration and Control Authority (Ethiopia)
From 30th April to 2nd May 2018, PAVIA will have its activities start through a joint kick off meeting with another EDCTP – funded consortium called PROFORMA that has overlapping objectives as PAVIA. The kick off meeting will be held in Dar es Salaam in Tanzania.
EDCTP (The European & Developing Countries Clinical Trials Partnership) is a public-public partnership between 14 European and 15 sub-Saharan African countries. The EDCTP2 programme funding PAVIA is supported under Horizon 2020, the European Union’s Framework Programme for Research and Innovation.
Developed by: Hilinaab